Stocks Health care OCUL
NASDAQ · Health careOcular Therapeutix, Inc (OCUL)
Ocular Therapeutix, Inc brought in $52.1M of revenue over the twelve months to June 30, 2026, down 8.1% from a year earlier. It posted a net loss of $301.4M. In fiscal 2025 capital spending exceeded operating cash flow by $216.9M. At June 30, 2026 it held $598.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 3, 2026.
What Ocular Therapeutix, Inc does
Ocular Therapeutix, Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker OCUL.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $52M | -$265.9M | -$1.42 | -$216.9M |
| 2024 | $63.7M | -$193.5M | -$1.22 | -$136M |
| 2023 | $58.4M | -$80.7M | -$1.02 | -$76.3M |
| 2022 | $51.5M | -$71M | -$0.97 | -$63.3M |
| 2021 | $43.5M | -$6.6M | -$0.98 | -$66.7M |
| 2020 | $17.4M | -$155.6M | -$2.56 | -$54.4M |
Latest SEC filings
What Ocular Therapeutix, Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 3, 2026
- August 3, 2026Quarterly report 10-Q · period to June 30, 2026
- August 3, 2026
- July 29, 2026Passive stake changed SCHEDULE 13G/A
- June 12, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 5, 2026Quarterly report 10-Q · period to March 31, 2026
- May 5, 2026
- April 30, 2026Additional proxy material DEFA14A
- April 30, 2026Proxy statement DEF 14A
Questions about OCUL
What does Ocular Therapeutix, Inc do?
Ocular Therapeutix, Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker OCUL.
Is Ocular Therapeutix, Inc profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $301.4M on revenue of $52.1M.
How much revenue does Ocular Therapeutix, Inc make?
Over the twelve months to June 30, 2026 Ocular Therapeutix, Inc reported revenue of $52.1M. That is 8.1% less than a year earlier.
When did Ocular Therapeutix, Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 3, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 2, 2026.
Similar companies
Follow OCUL
Get an email when Ocular Therapeutix, Inc files with the SEC: results, executive changes, material agreements and annual reports.
Follow OCUL: get an email when it filesWhere the numbers come from
Financial figures are the values Ocular Therapeutix, Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.